Influence of Cost in the CRO Selection Process
Applied Clinical Trials
Industry Standard Research
Industry Standard Research (ISR) does a significant amount of research in the area of sponsor/CRO relationships. In the course of conducting this research, ISR developed a unique understanding of the process that sponsors go through to select a CRO and the criteria used to evaluate those invited to bid for a particular piece of work. One common observation from CROs is surprising: cost does not rise to the top of their list of selection drivers. In fact, across all phases of research, cost invariably shows up well down the list, behind therapeutic expertise, quality project managers, and prior relationships. Where does this disconnect come from?
Sponsors were then polled to shed some light on their side of the question. In addition to asking what drives their selection, sponsors were asked to speak about the drivers of non-awards. What causes them to rule out a CRO?
By a substantial margin, high cost is the leading response, lending credence to the notion that sponsors are perhaps more price sensitive in their selection process than they indicate in direct responses. This led to the conclusion that while cost is unlikely to win most bids for a service provider, it can certainly lose a bid.
—Industry Standard Research, www.ISRreports.com.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
